報價延遲最少15分鐘:2025/06/01 00:30 EDT
|
|
|
|
|
||||||||||||
|
|
|
|
|
0.3001 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-0.81/-0.58
|
|
企業價值
49.26M
|
| 資產負債 |
|
每股賬面淨值
0.79
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
0
|
|
每股收益
--
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/06/01 00:30 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Elevation Oncology Inc is an oncology company focused on the development of selective cancer therapies to treat patients across a range of solid tumors with unmet medical needs. Its product candidate, EO-3021 (also known as SYSA1801 or CPO102), is an ADC comprised of a fully human anti-Claudin 18.2 immunoglobulin G1 (IgG1) monoclonal antibody (mAb) site-specifically conjugated with a cleavable linker to the cytotoxic monomethyl auristatin E (MMAE) payload. Claudin 18.2 is overexpressed in several types of cancers, including gastric, esophageal, pancreatic, ovarian and lungon. |